LNSRMEDIUM SIGNALFINANCIAL10-K

LNSR shows concerning cash burn and substantially higher operating expenses alongside significant inventory buildup, while a terminated merger agreement introduces new litigation risks.

The company terminated a merger agreement and added new risk disclosures around potential shareholder litigation and business impact from the deal's collapse. Combined with deteriorating cash position and meaningfully expanded SG&A expenses, this suggests operational stress despite inventory growth that may indicate production scaling efforts.

Comparing 2026-03-31 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

LNSR's financial position shows mixed signals with inventory nearly doubling to $21.5M and total liabilities rising 75.6% to $83.7M, while cash declined 20.2% to $13.0M. SG&A expenses expanded substantially to $45.2M, indicating significant operational scaling or deal-related costs, though interest expense declined 33% providing some relief. The combination of higher inventory, reduced cash, and substantially higher operating expenses suggests the company is investing heavily in growth while burning cash, creating a need to monitor liquidity closely.

FINANCIAL STATEMENT CHANGES
Inventory
Balance Sheet
+88.3%
$11.4M$21.5M

Inventory surged 88.3% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Liabilities
Balance Sheet
+75.6%
$47.7M$83.7M

Liabilities grew 75.6% — significant increase in debt or obligations, assess impact on financial flexibility.

SG&A Expense
P&L
+70.5%
$26.5M$45.2M

SG&A up 70.5% — significant increase in sales or administrative costs, monitor impact on operating leverage.

Capital Expenditure
Cash Flow
-46.8%
$156K$83K

Capex reduced 46.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
-33%
$2.0M$1.3M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
-20.2%
$16.3M$13.0M

Cash decreased 20.2% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
+11.4%
$42.0M$46.8M

Current assets grew 11.4% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-02-27
ADDED
As of February 28, 2026, there were 12,095,631 shares of the registrant s common stock outstanding.
The principal risks and uncertainties affecting our business include the following: The announcement of the termination of the Merger Agreement could negatively impact our business, financial condition, results of operations or our stock price.
We may experience shareholder litigation related to the termination of the Merger Agreement, which could result in payment of damages.
Our results have been in the past, and could be in the future, adversely affected by economic uncertainty or deteriorations in economic conditions.
Food and Drug Administration, or FDA, in June 2022, and we executed a controlled and targeted initial launch of the ALLY System in August 2022.
According to the 2025 Cataract Surgical Equipment Market Report, global estimated cataract surgery and refractive lens exchange surgical procedures (cataract surgery) are expected to grow from 33.1 million in 2025 to 39.6 million in 2030.
In the United States, cataract surgery is expected to increase from almost 5.1 million procedures in 2025 to approximately 5.9 million in 2030.
However, in 2025, only 1 million of the global cataract surgeries were performed using a laser.
This is expected to grow to an estimated 1.2 million of the global cataract procedures in 2030.
The use of a laser during cataract surgery allows the surgeon to use advanced imaging techniques to design a precise surgical plan and a femtosecond laser, the same type of laser engine used to cut the flaps in LASIK corrective procedures, to make the AIs and perform the capsulorhexis.
REMOVED
As of January 31, 2025, there were 11,789,492 shares of the registrant s common stock outstanding.
The principal risks and uncertainties affecting our business include the following: Our results have been in the past, and could be in the future, adversely affected by economic uncertainty or deteriorations in economic conditions.
Food and Drug Administration, or FDA, in June 2022, and we began commercialization of the ALLY System in August 2022.
In 2024, we obtained certification of our ALLY System under the Medical Devices Regulation in the European Union, or EU, and we have also received regulatory clearance in India, Taiwan, and certain other countries.
In addition, we are pursuing additional marketing or certification applications through our distributors in South Korea and China.
According to the 2024 Cataract Surgical Equipment Market Report, global estimated cataract surgery and refractive lens exchange surgical procedures (cataract surgery) are expected to grow from 31.9 million in 2024 to 37.8 million in 2029.
In the United States, cataract surgery is expected to increase from almost 4.9 million procedures in 2024 to approximately 5.7 million in 2029.
By contrast, worldwide laser-assisted cataract surgery is expected to grow from just over 1 million procedures in 2024 to an estimated 1.2 million procedures in 2029.
Laser-assisted cataract surgery involves the same steps as traditional surgery but uses advanced imaging techniques to design a precise surgical plan and a femtosecond laser, the same type of laser engine used to cut the flaps in LASIK corrective procedures, to make the AIs and perform the capsulorhexis.
For example, some of the benefits of laser-assisted cataract surgery include: Improved accuracy .
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →